PL3285755T3 - Chlorowodorek kreatyny do leczenia choroby Huntingtona - Google Patents
Chlorowodorek kreatyny do leczenia choroby HuntingtonaInfo
- Publication number
- PL3285755T3 PL3285755T3 PL16783719T PL16783719T PL3285755T3 PL 3285755 T3 PL3285755 T3 PL 3285755T3 PL 16783719 T PL16783719 T PL 16783719T PL 16783719 T PL16783719 T PL 16783719T PL 3285755 T3 PL3285755 T3 PL 3285755T3
- Authority
- PL
- Poland
- Prior art keywords
- huntington
- disease
- treatment
- creatine hydrochloride
- creatine
- Prior art date
Links
- DGOAYHVIVJYHKU-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrochloride Chemical compound Cl.NC(=N)N(C)CC(O)=O DGOAYHVIVJYHKU-UHFFFAOYSA-N 0.000 title 1
- 208000023105 Huntington disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562150113P | 2015-04-20 | 2015-04-20 | |
| PCT/US2016/028357 WO2016172148A1 (en) | 2015-04-20 | 2016-04-20 | Compositions and methods for neuroprotection and treatment of neurodegeneration |
| EP16783719.4A EP3285755B1 (en) | 2015-04-20 | 2016-04-20 | Creatine hydrochloride for the treatment of huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3285755T3 true PL3285755T3 (pl) | 2022-02-21 |
Family
ID=57128180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16783719T PL3285755T3 (pl) | 2015-04-20 | 2016-04-20 | Chlorowodorek kreatyny do leczenia choroby Huntingtona |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10245245B2 (pl) |
| EP (1) | EP3285755B1 (pl) |
| JP (2) | JP6882191B2 (pl) |
| CA (1) | CA2983151C (pl) |
| ES (1) | ES2903136T3 (pl) |
| PL (1) | PL3285755T3 (pl) |
| WO (1) | WO2016172148A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016172148A1 (en) * | 2015-04-20 | 2016-10-27 | Vireo Systems, Inc. | Compositions and methods for neuroprotection and treatment of neurodegeneration |
| US11154499B2 (en) | 2018-03-27 | 2021-10-26 | Thermolife International, Llc | Creatine and/or creatinine compositions and related methods |
| WO2019191338A1 (en) * | 2018-03-27 | 2019-10-03 | Thermolife International, Llc | Creatine and/or creatinine compositions and related methods |
| US11260096B2 (en) | 2019-06-28 | 2022-03-01 | Thermolife International, Llc | Compositions for creatine supplementation in creatine non-responders |
| EP4247358A4 (en) * | 2020-11-23 | 2024-10-16 | VIREO Systems, Inc. | Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4151996A (en) | 1994-11-08 | 1996-05-31 | Avicena Group, Inc. | Use of creatine or creatine analogs for the treatment of diseases of the nervous system |
| MXPA03007757A (es) * | 2001-03-02 | 2004-03-16 | Howard Foundation | Composiciones que contienen creatina y creatinina. |
| US8354450B2 (en) | 2003-05-15 | 2013-01-15 | Vireo Systems, Inc. | Creatine oral supplementation using creatine hydrochloride salt |
| US7608641B2 (en) * | 2003-05-15 | 2009-10-27 | Board Of Regents Of The University Of Nebraska | Creatine oral supplementation using creatine hydrochloride salt |
| CA2610856A1 (en) | 2005-06-13 | 2006-12-28 | Stratagene California | System and method for fluorescence excitation and detection having distinct optical paths |
| AU2007249847A1 (en) | 2006-05-11 | 2007-11-22 | Avicena Group, Inc. | Methods of treating a neurological disorder with creatine monohydrate |
| US7683043B2 (en) | 2006-06-06 | 2010-03-23 | Xenoport, Inc. | Creatine phosphate analog prodrugs, compositions and uses thereof |
| AU2008261094B2 (en) | 2007-06-05 | 2014-07-17 | Cryxa Llc | Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine |
| US8445466B2 (en) | 2010-04-08 | 2013-05-21 | John H. Owoc | Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof |
| WO2015095199A1 (en) * | 2013-12-16 | 2015-06-25 | Vireo Systems, Inc. | Method and composition for treating osteoarthritis |
| WO2016172148A1 (en) * | 2015-04-20 | 2016-10-27 | Vireo Systems, Inc. | Compositions and methods for neuroprotection and treatment of neurodegeneration |
-
2016
- 2016-04-20 WO PCT/US2016/028357 patent/WO2016172148A1/en not_active Ceased
- 2016-04-20 ES ES16783719T patent/ES2903136T3/es active Active
- 2016-04-20 CA CA2983151A patent/CA2983151C/en active Active
- 2016-04-20 JP JP2017555718A patent/JP6882191B2/ja active Active
- 2016-04-20 US US15/133,501 patent/US10245245B2/en active Active
- 2016-04-20 EP EP16783719.4A patent/EP3285755B1/en active Active
- 2016-04-20 PL PL16783719T patent/PL3285755T3/pl unknown
-
2019
- 2019-04-01 US US16/371,779 patent/US10583105B2/en active Active
-
2020
- 2020-03-09 US US16/812,835 patent/US11160776B2/en active Active
-
2021
- 2021-05-06 JP JP2021078285A patent/JP2021120388A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3285755B1 (en) | 2021-10-13 |
| US10583105B2 (en) | 2020-03-10 |
| US20190224151A1 (en) | 2019-07-25 |
| ES2903136T3 (es) | 2022-03-31 |
| JP2018513204A (ja) | 2018-05-24 |
| US20200316000A1 (en) | 2020-10-08 |
| US20160303061A1 (en) | 2016-10-20 |
| US11160776B2 (en) | 2021-11-02 |
| JP2021120388A (ja) | 2021-08-19 |
| US10245245B2 (en) | 2019-04-02 |
| CA2983151A1 (en) | 2016-10-27 |
| WO2016172148A1 (en) | 2016-10-27 |
| CA2983151C (en) | 2024-03-05 |
| EP3285755A1 (en) | 2018-02-28 |
| JP6882191B2 (ja) | 2021-06-02 |
| EP3285755A4 (en) | 2018-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281633A (en) | Methods for treating Huntington's disease | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| IL271046B1 (en) | Compounds for the treatment of Huntington's disease | |
| IL265206A (en) | Antisense oligonucleotides for the treatment of eye disease | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| IL253945A0 (en) | kdm1a inhibitors to treat the disease | |
| IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
| ZA201608108B (en) | Huntington's disease therapeutic compounds | |
| EP3268086A4 (en) | Lsd for the treatment of alzheimer's disease | |
| IL252433B (en) | Methods for treating Alzheimer's disease | |
| IL254142B (en) | Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| IL255506A (en) | A method for treating a neurological disease | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| EP3310377A4 (en) | Method of treating crohn's disease | |
| PL3484475T3 (pl) | 1-Metylonikotynamid do leczenia choroby układu krążenia | |
| EP3244897A4 (en) | Methods for treating alzheimer's disease | |
| IL272422A (en) | Methods for treating diseases of the meninges | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| DK3148588T3 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| GB201518052D0 (en) | Parkinson's disease treatment | |
| GB201511453D0 (en) | Treatment of alzheimer's disease | |
| GB201504144D0 (en) | Treatment of Parkinson's disease |